ECA stack

Ephedrine, caffeine, and aspirin drug combination formerly promoted for weight loss and stimulation

ECA stack is a nonstandard drug and supplement combination consisting of ephedrine, caffeine, and aspirin. The related EC stack omits aspirin and contains only ephedrine and caffeine. ECA and EC combinations were widely promoted in the 1990s and early 2000s for weight loss, thermogenesis, appetite suppression, energy, and bodybuilding. Because ephedra and ephedrine-containing weight-loss products were associated with serious adverse events, including hypertension, heart attack, stroke, seizure, psychiatric symptoms, and sudden death, marketing of ephedra or ephedrine alkaloid dietary supplements is now restricted or prohibited in several countries.Final Rule Declaring Dietary Supplements Containing Ephedrine Alkaloids Adulterated(link). U.S. Food and Drug Administration.Ephedra: Usefulness and Safety(link). National Center for Complementary and Integrative Health.

Historically, controlled trials found that ephedrine plus caffeine could produce modest short-term weight loss compared with placebo, but the benefit was limited and long-term safety data were insufficient. A major 2003 meta-analysis concluded that ephedrine and ephedra promoted modest short-term weight loss, approximately 0.9 to 1.0 kg per month more than placebo, but increased the odds of psychiatric, autonomic, gastrointestinal, and heart palpitation symptoms."Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis".JAMA.2003;289(12)

1537-1545.doi:10.1001/jama.289.12.1537.PMID:12672771.

ECA stack use is now largely of historical interest in obesity medicine, sports nutrition, supplement regulation, and public health. It is not considered a preferred or modern treatment for obesity. Current evidence-based obesity treatment emphasizes nutrition therapy, physical activity, behavioral treatment, anti-obesity medications, treatment of obesity-related conditions, and bariatric surgery or metabolic surgery when indicated.

Terminology

• ECA stack - Combination of ephedrine, caffeine, and aspirin.
• EC stack - Combination of ephedrine and caffeine without aspirin.
• Ephedrine - Sympathomimetic alkaloid and drug with stimulant and bronchodilator effects.
• Ephedra - Plant genus containing ephedrine alkaloids; also known as ma huang in traditional medicine.
• Ma huang - Traditional name for ephedra-containing herbal preparations.
• Caffeine - Central nervous system stimulant found in coffee, tea, energy drinks, and medications.
• Aspirin - Acetylsalicylic acid, a nonsteroidal anti-inflammatory drug and antiplatelet agent.
• Thermogenesis - Heat production by the body, sometimes targeted in weight-loss supplements.
• Anorectic - Appetite-suppressing agent.
• Stimulant - Substance that increases central nervous system or sympathetic activity.
• Dietary supplement - Product regulated differently from prescription and nonprescription drugs in many countries.

Components

Ephedrine

Ephedrine is a sympathomimetic compound that stimulates adrenergic receptors and increases release of norepinephrine. It can increase heart rate, blood pressure, alertness, and bronchodilation. Ephedrine has been used medically as a bronchodilator and for selected clinical indications, but nonmedical weight-loss use is restricted because of safety concerns.

• Sympathomimetic drug - Drug that mimics sympathetic nervous system activity.
• Adrenergic receptor - Receptor activated by adrenaline-like compounds.
• Norepinephrine - Neurotransmitter involved in alertness, blood pressure, and sympathetic response.
• Bronchodilator - Drug that widens airways.
• Vasopressor - Drug that raises blood pressure in selected medical settings.
• Stimulant - Drug that increases alertness or physiologic activation.

Caffeine

Caffeine is a methylxanthine stimulant that blocks adenosine receptors and can increase alertness, heart rate, and metabolic rate. In EC or ECA combinations, caffeine was used to amplify stimulant and thermogenic effects.

• Adenosine receptor antagonist - Mechanism by which caffeine increases alertness.
• Methylxanthine - Chemical class that includes caffeine and theophylline.
• Central nervous system stimulant - Drug that increases wakefulness or arousal.
• Energy drink - Common source of caffeine.
• Insomnia - Common caffeine-related adverse effect.
• Palpitation - Awareness of heartbeat that may occur with caffeine or ephedrine.

Aspirin

Aspirin was historically added to some ECA regimens based on the idea that prostaglandin inhibition might prolong thermogenesis. The clinical value of aspirin in this combination was never clearly established, and aspirin adds risks such as gastrointestinal bleeding, ulceration, allergic reactions, and drug interactions.

• Nonsteroidal anti-inflammatory drug - Drug class that includes aspirin.
• Cyclooxygenase inhibitor - Mechanism of aspirin and many NSAIDs.
• Antiplatelet drug - Aspirin reduces platelet aggregation.
• Gastrointestinal bleeding - Important aspirin-related risk.
• Peptic ulcer disease - Potential complication of aspirin use.
• Reye syndrome - Rare but serious risk when aspirin is used in children or teenagers with viral illness.

Proposed mechanism

The ECA stack was promoted as a thermogenic and appetite-suppressing combination. The proposed mechanism involved stimulation of the sympathetic nervous system by ephedrine, amplification by caffeine, and possible prolongation of thermogenesis through aspirin-mediated prostaglandin inhibition. The aspirin component is now often viewed as unnecessary or poorly supported.

• Sympathetic nervous system - System involved in fight-or-flight physiology.
• Catecholamine - Class of signaling molecules including epinephrine and norepinephrine.
• Lipolysis - Breakdown of stored fat into fatty acids.
• Basal metabolic rate - Energy expenditure at rest.
• Energy expenditure - Calories used by the body.
• Appetite suppression - Reduced desire to eat.
• Thermogenic supplement - Supplement marketed to increase energy expenditure.
• Prostaglandin - Lipid mediator affected by aspirin and other NSAIDs.

Historical use

ECA and EC combinations became popular in bodybuilding, weight-loss, and athletic communities during the 1990s and early 2000s. Many products used herbal ephedra rather than pharmaceutical ephedrine. Products were often marketed as "fat burners," thermogenic supplements, pre-workout stimulants, or energy enhancers.

This popularity declined sharply after regulatory warnings, adverse-event reports, high-profile deaths, sports bans, and the U.S. FDA's 2004 final rule declaring dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable risk.Final Rule Declaring Dietary Supplements Containing Ephedrine Alkaloids Adulterated Because They Present an Unreasonable Risk(link). Federal Register.February 11, 2004.

Evidence for weight loss

Clinical evidence suggests that ephedrine-caffeine combinations can produce modest short-term weight loss, but the effect is small compared with modern obesity therapies and is limited by safety concerns.

• Short-term weight loss - Trials showed modest reductions over weeks to months.
• Placebo-controlled trial - Study design used to compare active treatment with placebo.
• Meta-analysis - Pooled analysis of multiple studies.
• Obesity - Chronic disease involving excess adiposity and health risk.
• Anti-obesity medication - Medication approved for chronic weight management.
• Lifestyle intervention - Nutrition, physical activity, and behavioral change.
• Risk-benefit analysis - Essential because modest benefit must be weighed against adverse effects.

A 2003 JAMA meta-analysis reported that ephedrine and ephedra promoted modest short-term weight loss but also increased adverse symptoms. The authors found no evidence establishing long-term benefit and insufficient data to assess rare but serious adverse events."Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis".JAMA.2003;289(12)

1537-1545.doi:10.1001/jama.289.12.1537.PMID:12672771.

Evidence for athletic performance

ECA products were marketed to athletes for energy, endurance, focus, and fat loss. Evidence for meaningful athletic performance improvement is limited and inconsistent. The 2003 JAMA review found no trials of ephedra for athletic performance and found ephedrine studies too heterogeneous to synthesize."Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis".JAMA.2003;289(12)

1537-1545.doi:10.1001/jama.289.12.1537.PMID:12672771.

Athletes should also consider anti-doping rules. The World Anti-Doping Agency lists ephedrine and methylephedrine as prohibited in competition when urinary concentration exceeds the specified threshold.The Prohibited List(link). World Anti-Doping Agency.

Health risks

ECA stack use can produce additive stimulant effects and increase risk of adverse events. Risk is higher with high doses, dehydration, heat exposure, intense exercise, underlying cardiovascular disease, hypertension, anxiety disorders, hyperthyroidism, stimulant use, or combinations with other sympathomimetic drugs.

Cardiovascular risks

• Hypertension - Elevated blood pressure.
• Tachycardia - Fast heart rate.
• Palpitation - Awareness of heartbeat.
• Arrhythmia - Abnormal heart rhythm.
• Myocardial infarction - Heart attack.
• Stroke - Brain injury due to blocked or ruptured blood vessel.
• Sudden cardiac death - Rare but reported with stimulant products.
• Vasospasm - Narrowing of blood vessels.
• Cardiomyopathy - Heart muscle dysfunction, rarely associated with stimulant exposure.

Neurologic and psychiatric risks

• Anxiety - Can be worsened by stimulants.
• Insomnia - Common with caffeine and ephedrine.
• Irritability - Stimulant-related adverse effect.
• Tremor - Shaking caused by adrenergic stimulation.
• Seizure - Serious neurologic adverse event reported with ephedra products.
• Psychosis - Rare but serious psychiatric adverse effect.
• Headache - Common stimulant-related symptom.
• Panic attack - May be triggered or worsened by stimulants.

Gastrointestinal and bleeding risks

• Nausea - Common adverse effect.
• Heartburn - Can be worsened by caffeine or aspirin.
• Peptic ulcer disease - Aspirin-related risk.
• Gastrointestinal bleeding - Serious aspirin-related adverse event.
• Aspirin allergy - Contraindication to aspirin-containing combinations.
• Drug interaction - Aspirin, caffeine, and ephedrine can interact with other medications.

Contraindications and cautions

ECA or EC combinations are especially risky in people with certain conditions.

• Hypertension
• Coronary artery disease
• Arrhythmia
• Stroke history
• Seizure disorder
• Hyperthyroidism
• Anxiety disorder
• Panic disorder
• Bipolar disorder
• Insomnia
• Glaucoma
• Benign prostatic hyperplasia
• Peptic ulcer disease
• Bleeding disorder
• Kidney disease
• Liver disease
• Pregnancy
• Breastfeeding
• Adolescent use
• Use of monoamine oxidase inhibitors
• Use of other stimulants
• Use of anticoagulants or antiplatelet drugs

Drug interactions

Potential interactions include additive stimulation, blood pressure elevation, bleeding risk, and altered medication effects.

• Monoamine oxidase inhibitor - Can produce dangerous hypertensive reactions with sympathomimetics.
• Amphetamine - Additive stimulant effect.
• Methylphenidate - Additive stimulant effect.
• Pseudoephedrine - Additive sympathomimetic effect.
• Phenylephrine - Additive adrenergic effect.
• Albuterol - May increase tremor, tachycardia, or palpitations.
• Warfarin - Aspirin can increase bleeding risk.
• Direct oral anticoagulant - Aspirin can increase bleeding risk.
• Selective serotonin reuptake inhibitor - Aspirin may increase bleeding risk.
• Nonsteroidal anti-inflammatory drug - Combined aspirin and NSAID use can increase gastrointestinal risk.
• Antihypertensive drug - Stimulants can oppose blood pressure control.
• Thyroid hormone - May increase sensitivity to adrenergic symptoms.

Legal and regulatory status

Legal status varies by country and by whether ephedrine is sold as a medicine, a dietary supplement ingredient, a natural health product, a controlled precursor chemical, or a sports-related substance.

United States

In the United States, dietary supplements containing ephedrine alkaloids are illegal to market because they are considered adulterated under FDA regulations. The FDA's rule applies to dietary supplements containing ephedrine alkaloids, including ephedra-derived products.Final Rule Declaring Dietary Supplements Containing Ephedrine Alkaloids Adulterated(link). U.S. Food and Drug Administration.

Ephedrine can still appear in certain regulated drug products, such as some bronchodilator products for temporary relief of mild asthma symptoms, but these are not weight-loss supplements. Retail sale of products containing ephedrine, pseudoephedrine, or phenylpropanolamine is restricted under the Combat Methamphetamine Epidemic Act because these substances can be diverted for illicit methamphetamine production. Federal rules include daily and monthly purchase limits and recordkeeping requirements.Combat Methamphetamine Epidemic Act of 2005 General Information(link). U.S. Drug Enforcement Administration.Legal Requirements for the Sale and Purchase of Drug Products Containing Pseudoephedrine, Ephedrine, and Phenylpropanolamine(link). U.S. Food and Drug Administration.

Canada

Health Canada has advised consumers not to use ephedrine and caffeine combinations for weight loss because of risk of serious and possibly fatal effects. Health Canada previously requested recall of ephedrine products exceeding certain dose limits, products combined with stimulants such as caffeine, and products marketed for weight loss or bodybuilding.Health Canada advises consumers not to use weight loss products containing ephedrine and caffeine(link). Health Canada.

Denmark

Denmark previously approved a prescription ephedrine-caffeine product called Letigen, containing synthetic ephedrine and caffeine, for obesity treatment. It was withdrawn from marketing in 2002 after adverse-event concerns. A 2008 registry-based case-crossover study found that prescribed ephedrine-caffeine use was not associated with a substantially increased risk of serious cardiovascular outcomes in that study, although the authors' findings do not remove broader safety concerns about unregulated supplement use."Use of a prescribed ephedrine/caffeine combination and the risk of serious cardiovascular events: a registry-based case-crossover study".American Journal of Epidemiology.2008;168(8)

966-973.doi:10.1093/aje/kwn191.PMID:18756018.

Sports and anti-doping

Ephedrine is regulated in competitive sport. WADA prohibits ephedrine and methylephedrine in competition when urinary concentration exceeds the listed threshold. Athletes are responsible for checking current anti-doping rules before using any stimulant, cold medicine, asthma product, or supplement.The Prohibited List(link). World Anti-Doping Agency.

Modern obesity treatment context

The ECA stack is not a modern preferred treatment for obesity. Current evidence-based obesity care generally uses a chronic disease model and may include lifestyle intervention, nutrition therapy, physical activity, behavioral treatment, management of sleep and mental health, anti-obesity medications, and metabolic surgery when indicated.

• Lifestyle medicine - Nutrition, physical activity, sleep, stress management, and behavior change.
• Medical weight management - Physician-supervised obesity care.
• Anti-obesity medication - Evidence-based medication approved for chronic weight management.
• GLP-1 receptor agonist - Medication class used for diabetes and obesity.
• Dual incretin receptor agonist - Medication class including tirzepatide.
• Orlistat - Lipase inhibitor approved for weight management.
• Phentermine/topiramate - Combination anti-obesity medication.
• Naltrexone/bupropion - Combination anti-obesity medication.
• Semaglutide - GLP-1 receptor agonist approved for chronic weight management.
• Tirzepatide - GIP/GLP-1 receptor agonist approved for chronic weight management.
• Bariatric surgery - Surgical treatment for obesity.
• Metabolic surgery - Surgery improving obesity-related metabolic disease.

Comparison with modern treatments

Compared with modern anti-obesity therapies, ECA/EC combinations have limited short-term efficacy and more problematic stimulant-related safety concerns.

• Efficacy - Ephedrine-caffeine weight loss is modest and short-term.
• Long-term data - Long-term safety and efficacy data are limited.
• Cardiovascular safety - Stimulant effects create concern in susceptible people.
• Regulatory status - Ephedra-containing supplements are illegal to market in the United States.
• Evidence-based medicine - Modern obesity treatment favors regulated therapies with clinical outcome data.
• Patient safety - Weight-loss therapy should consider blood pressure, heart disease, psychiatric history, medications, and pregnancy status.

Public health concerns

ECA stack history is important in public health because it illustrates risks from stimulant weight-loss supplements, adverse-event surveillance, supplement regulation, sports doping, and precursor chemical control.

• Dietary supplement safety - Supplements can cause serious harms despite being marketed as natural.
• Adverse event reporting - Safety signal detection influenced ephedra regulation.
• Supplement adulteration - Some products marketed for weight loss may contain undeclared drugs.
• Methamphetamine precursor - Ephedrine and pseudoephedrine can be diverted for illicit methamphetamine production.
• Over-the-counter drug regulation - Ephedrine drug products are regulated differently from supplements.
• Bodybuilding supplement - High-risk supplement category.
• Weight-loss supplement - Category frequently associated with misleading claims.
• Consumer protection - Regulatory oversight aims to reduce unsafe marketing.
• Sports doping - Stimulants may violate anti-doping rules.

Patient education

Patients should not assume that a product is safe because it is "natural," herbal, or sold online. Ephedra and ephedrine-containing weight-loss products have been associated with serious adverse effects. People seeking weight loss should use evidence-based approaches under appropriate medical supervision, especially if they have high blood pressure, heart disease, arrhythmia, anxiety, thyroid disease, pregnancy, or are taking prescription medications.

• Weight loss should be managed with safe, sustainable, evidence-based care.
• Obesity is a chronic medical condition, not a personal failure.
• Hypertension and stimulant use can be a dangerous combination.
• Palpitations, chest pain, fainting, severe headache, confusion, or neurologic symptoms require urgent care.
• Caffeine can worsen anxiety, insomnia, palpitations, and blood pressure.
• Aspirin can cause bleeding and is not appropriate for everyone.
• Ephedra-containing supplements should be avoided.
• Dietary supplement labels may not guarantee safety or effectiveness.
• Anti-obesity medication should be discussed with a qualified clinician.
• Exercise and nutrition plans should be individualized.

When to seek medical care

Urgent medical care is needed if a person using stimulants or weight-loss supplements develops symptoms suggesting cardiovascular, neurologic, psychiatric, or allergic complications.

• Chest pain
• Shortness of breath
• Palpitations
• Fainting
• Severe headache
• Stroke symptoms
• Seizure
• Confusion
• Psychosis
• Severe anxiety
• High blood pressure
• Vomiting blood
• Black stool
• Allergic reaction
• Pregnancy with stimulant or supplement exposure

See also

• Ephedrine
• Ephedra
• Caffeine
• Aspirin
• Weight-loss supplement
• Dietary supplement
• Obesity
• Anti-obesity medication
• Bodybuilding supplement
• Stimulant
• Sympathomimetic drug
• Thermogenesis
• Methamphetamine
• Combat Methamphetamine Epidemic Act of 2005
• Sports doping
• World Anti-Doping Agency
• Drug safety
• Adverse drug reaction
• Supplement adulteration

Further reading

• Final Rule Declaring Dietary Supplements Containing Ephedrine Alkaloids Adulterated(link). U.S. Food and Drug Administration.
• Final Rule Declaring Dietary Supplements Containing Ephedrine Alkaloids Adulterated Because They Present an Unreasonable Risk(link). Federal Register.February 11, 2004.
• Ephedra: Usefulness and Safety(link). National Center for Complementary and Integrative Health.
• "Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis".JAMA.2003;289(12)

1537-1545.doi:10.1001/jama.289.12.1537.PMID:12672771.

• "Use of a prescribed ephedrine/caffeine combination and the risk of serious cardiovascular events: a registry-based case-crossover study".American Journal of Epidemiology.2008;168(8)

966-973.doi:10.1093/aje/kwn191.PMID:18756018.

• Health Canada advises consumers not to use weight loss products containing ephedrine and caffeine(link). Health Canada.
• Combat Methamphetamine Epidemic Act of 2005 General Information(link). U.S. Drug Enforcement Administration.
• The Prohibited List(link). World Anti-Doping Agency.

External links

• NCCIH - Ephedra: Usefulness and Safety
• FDA - Dietary supplements containing ephedrine alkaloids
• Federal Register - Ephedrine alkaloid dietary supplement final rule
• Health Canada - Ephedrine and caffeine warning
• DEA - Combat Methamphetamine Epidemic Act
• WADA - Prohibited List
• JAMA meta-analysis - Ephedra and ephedrine for weight loss and athletic performance
• Danish registry study - Prescribed ephedrine/caffeine and cardiovascular risk